Klin Onkol 2016; 29(2): 107-110. DOI: 10.14735/amko2016107.
Thanks to a multidisciplinary approach, testicular germinative tumors are now assigned to
a group of highly curable oncologic diseases with favorable prognoses. Despite the gradual increase in the incidence of this type of cancer in recent years, mortality remains low. Yet, guidelines for postoperative treatment of stage I non-seminomatous germ cell testicular tumors
remain inconsistent due to the low number of randomized studies. The probability of relapse
is strongly associated with the occurrence of lymphangiogenesis. The period after primarily
orchiectomy can be utilized for close monitoring, cisplatin-based adjuvant chemotherapy, or
retroperitoneal lymphadenectomy. All variants of therapy off er a cure rate of about 99%. The
use of adjuvant chemotherapy, as well as retroperitoneal lymph node dissection, is associated
with acute and late adverse eff ects. The eff ort to minimize side eff ects with preserving the
lowest number of relapses resulted in the need for comparing the number of chemotherapy
cycles and chemotherapy vs. retroperitoneal lymphadenectomy. The aim of this review is to
evaluate the diff erent treatment modalities for stage I testicular germ cell tumors with respect
to their effi cacy and toxicity.
